|
Introduction
While each viral indication, ranging from HIV to influenza, presents unique challenges, there are a number of issues that companies developing and marketing drugs across this field face. Curative therapies are rare, drug resistance is becoming increasingly problematic and the introduction of novel vaccines threatens the market for many antivirals.
Scope of this Report
- Detailed analysis of the global antiviral market, focusing on HIV, hepatitis, herpes and influenza
- Assessment of each viral indication, characterized by 2002 market value, forecasted growth and current clinical unmet need
- Insight into antiviral research and development activity
- Discussion of the various options for more effective life cycle and portfolio management strategy
Report Highlights
- The antiviral market is set to demonstrate positive growth up until 2011, driven predominantly by the increased availability of hepatitis B treatments.
- Growing disease awareness, particularly of recently characterized infections, such as HCV, will continue to drive patient potential by increasing presentation rates.
- Broad-spectrum antivirals present companies with good opportunities to implement life-cycle management initiatives.
Key Reasons to buy this Report
- Determine the characteristics that define antiviral markets and their relative potential
- Understand the key drivers and resistors of antiviral market growth
- Identify life-cycle management options that help to optimize and extend product revenue
| 
View Cart
